Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia.

Bugarski-Kirola, Dragana; Nunez, Rene; Odetalla, Ramzey; Liu, I-Yuan; Turner, Mary Ellen

Bugarski-Kirola, Dragana; Nunez, Rene; Odetalla, Ramzey; Liu, I-Yuan; Turner, Mary Ellen.

Afiliación

Bugarski-Kirola D; Acadia Pharmaceuticals GmbH, Basel, Switzerland.
Nunez R; Acadia Pharmaceuticals Inc., San Diego, CA, United States.
Odetalla R; Acadia Pharmaceuticals Inc., San Diego, CA, United States.
Liu IY; Acadia Pharmaceuticals Inc., San Diego, CA, United States.
Turner ME; Acadia Pharmaceuticals Inc., San Diego, CA, United States.

Front Psychiatry ; 13: 892199, 2022.

Article en En | MEDLINE | ID: mdl-36147980

Palabras clave

QT interval; adjunctive therapy; antipsychotics; pimavanserin; schizophrenia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Front Psychiatry Año: 2022 Tipo del documento: Article País de afiliación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google